# Genfleet Therapeutics (Shanghai) Inc.: Phase 3 study in Colorectal Cancer (368 participants)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer |
| NCT ID | NCT07913360 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Colorectal Cancer |
| Intervention types | drug |
| Target enrollment | 368 |
| Posted | 2026-11-03 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 368 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07913360). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.